Zobrazeno 81 - 90
of 119
pro vyhledávání: '"Jianrong Wu"'
Autor:
Richard Gorlick, Jianrong Wu, Stephen T. Keir, Christopher L. Morton, E. Anders Kolb, C. Patrick Reynolds, John M. Maris, Malcolm A. Smith, Peter J. Houghton, Min H. Kang
Publikováno v:
Pediatric bloodcancer. 55(2)
Background Seneca Valley virus (NTX-010) is a non-recombinant, replication competent RNA virus that is undergoing phase 1 clinical trials in adults for tumors with neuroendocrine characteristics. Here we have evaluated the antitumor activity of NTX-0
Autor:
Richard B. Lock, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith, E. Anders Kolb, Hernan Carol, Richard Gorlick, John M. Maris, Christopher L. Morton, Peter J. Houghton, Min H. Kang, C. Patrick Reynolds
Publikováno v:
Pediatric bloodcancer. 55(1)
MLN8237 is a small molecule inhibitor of Aurora Kinase A (AURKA) that is currently in early phase clinical testing. AURKA plays a pivotal role in centrosome maturation and spindle formation during mitosis.MLN8237 was tested against the Pediatric Prec
Autor:
Jianrong Wu, Andrew M. Davidoff, A. Pillai, Wayne L. Furman, Chuang Wang, A.S. Pai Panandiker, John A. Sandoval, Victor M. Santana, Sara M. Federico
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 87:S598-S599
Autor:
Peter J. Houghton, M. Beth McCarville, Najat C. Daw, John C. Panetta, Fariba Navid, Carlos Rodriguez-Galindo, Jianrong Wu, Amar J. Gajjar, Sheri L. Spunt, Kristine R. Crews, Wayne L. Furman, Lisa M. McGregor, Clinton F. Stewart, Victor M. Santana
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(27)
Purpose To assess the maximum-tolerated dosages (MTDs), and dose-limiting toxicities (DLTs) of the epidermal growth factor receptor inhibitor gefitinib and of intravenous (IV) irinotecan when administered together in children with refractory solid tu
Autor:
Stephen T. Keir, Jianrong Wu, Peter J. Houghton, John M. Maris, Mayamin Tajbakhsh, Malcolm A. Smith, Joshua Courtright, Richard B. Lock, Christopher L. Morton, E. Anders Kolb, C. Patrick Reynolds
Publikováno v:
Pediatric bloodcancer. 51(1)
Background Sunitinib is an orally bioavailable, multi-targeted tyrosine kinase inhibitor with selectivity for PDGF receptors, VEGF receptors, FLT3, and KIT. Procedures Sunitinib was tested at concentrations ranging from 0.1 nM to 1.0 µM against 23 c
Autor:
Maryam Fouladi, Jianrong Wu, Melinda A. O'Shaughnessy, Alberto Broniscer, Clinton F. Stewart, Wayne L. Furman, Fred H. Laningham, Peter J. Houghton, Kristen Molina, Inga Luckett, Richard J. Gilbertson, Sheri L. Spunt
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(30)
PurposeTo determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic and pharmacodynamic properties of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, in children with refractory or recurrent soli
Autor:
Monika L. Metzger, Burgess B. Freeman, Najat C. Daw, Elizabeth Mullen, Fredric A. Hoffer, Jeffrey S. Dome, Clinton F. Stewart, Max J. Coppes, Ronald Grant, Catherine A. Billups, Murali Chintagumpala, Jianrong Wu, Carlos Alvarado
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(21)
Purpose A phase II study was conducted to evaluate the activity and safety of topotecan in pediatric patients with recurrent Wilms' tumor. Patients and Methods Patients with favorable histology Wilms' tumor (FHWT) and recurrence after at least one sa
Autor:
Robert K. Heck, Joseph Khoury, Juan Quintana, Najat C. Daw, Debbie Poe, Jianrong Wu, Catherine A. Billups, Aaron R. Weiss, Bhaskar N. Rao, Fredric A. Hoffer
Publikováno v:
Cancer. 109(8)
BACKGROUND. Telangiectatic osteosarcoma (TOS) is a rare subtype of osteosarcoma (OS). The authors reviewed their experience with TOS to characterize its histologic, radiologic, and clinical features. METHODS. The authors reviewed records, pathology m
Autor:
Malcolm A. Smith, Richard B. Lock, Raushan T. Kurmasheva, Sharon Shacham, Jianrong Wu, John M. Maris, Peter J. Houghton, Dmitry Lyalin, Hernan Carol, Stephen T. Keir, E. Anders Kolb, Yosef Landesman, Richard Gorlick
Publikováno v:
Cancer Research. 75:1616-1616
Background: Selinexor (KPT-330) is an inhibitor of the major nuclear export receptor, exportin 1 (XPO1, also termed chromosome region maintenance 1 or CRM1) that has demonstrated activity in preclinical models of several solid and hematological cance
Autor:
Peter J. Houghton, Brendan Murphy, Igor Dvorchik, Richard Gorlick, Anders Kolb, Patrick Reynolds, Han Yin, Jianrong Wu, Raushan T. Kurmasheva, John M. Maris, Malcolm A. Smith, Catherine A. Billups, Stephen T. Keir, Min H. Kang
Publikováno v:
Cancer Research. 75:1617-1617
Traditional approaches to evaluating antitumor agents using human tumor xenograft models have usually used 8-10 mice in control and treatment groups against a limited panel of tumor models. However, with increasing evidence of molecular/genetic subse